Atara partner Pierre Fabre resubmits tabelecleucel BLA to FDA
Bitget2026/09/30 12:06- Pierre Fabre Pharmaceuticals resubmitted the tabelecleucel BLA to the FDA for relapsed/refractory EBV+ PTLD in SOT or HCT patients.
- Atara Biotherapeutics expects to provide a revised PDUFA date once the FDA sets the review timeline.
- FDA approval would trigger a USD 31 million milestone payment to Atara under its Pierre Fabre commercialization deal.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin Edges Higher as Treasury Yields, Dollar Ease -- Market Talk
Morgan Stanley is tactically bullish on BHP (BHP.US): Two major copper mine catalysts may ignite the stock price in the next two months
Morgan Stanley maintains an "Overweight" rating on BHP Group, with an "attractive" industry outlook, and sets a target price of AUD 69.00 for its shares listed in Australia.
Bank of England hawkish official: Growth exceeds expectations and employment is resilient, which precisely proves that further rate hikes are necessary.
Megan Greene, a policymaker at the Bank of England, stated that the UK's economic growth surpassing expectations and the resilience of the job market indicate that the Bank of England's efforts to curb inflation are still insufficient.
Crypto prices
More
